and Fig. (2) , whereas cyclic and linear antagonist analogs are depicted in Fig. (3) and Fig. (4) , respectively. 
analog design studies for decades. Hundreds of peptide or non peptide agonists and antagonists of the AVP/OT receptors, several being of potential clinical value, have been synthesized and characterized, and presently are very useful pharmacological tools [16] . 
Agonist ligands.
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valuable probes in studying receptor visualization [21] . The synthesis and biological activity of novel fluorescent VP analogs was published in 1990 [22] . All these analogs were prepared by coupling again the appropriate fluorochrome to the e-amine group of the lysine residue in dLVP (see Fig. (1 ) ). The d[Lys 8 (carboxyfluorescein)]VP (7 ) and the d[Lys 8 (methylanthranilamide)]VP (8) were demonstrated to retain high affinity for the V2 receptor present in canine renal plasma membranes (32 and 8.8 nM whereas that of AVP was around 1 nM) and whole LLC-PK1 cells (390 and 38 nM compared to 9 nM for AVP), and able to stimulate adenylyl cyclase activity as efficiently as AVP. On the other hand, the dansyl derivative of dLVP (d[Lys 8 (dimethylaminonaphtalene-1-sulfonyl)]VP (9) , was unable to bind the receptor and activate cyclic adenosine monophosphate (cAMP) production. The first three ligands were defined as useful for the study of renal AVP receptors by fluorescence microscopy, particularly the fluorescein and rhodamine-labeled agonists. Whereas fluorescein exhibits low photostability, which restricts its use for imaging events occurring over long time periods, the rhodamine fluorophore is ideal in that it possesses a high molar extinction coefficient and does not photobleach readily. Taking into account these studies, designing of a fluorescent analog of AVP or OT retaining all agonistic properties of the natural hormones, was obviously much more successful when introducing a fluorophore at the side chain of the residue 8 of the peptide.
Cyclic and linear antagonist peptides.
The primary fluorescent antagonists of AVP/OT receptors were described in 1992 but were also nonselective. First, following the discovery that requirement of cyclic conformation of peptide antagonists in binding to AVP receptor is not necessary [23] , the classical fluorophore fluorescein was added to the N-terminus of a linear antagonist having a high affinity for both the V1a and V2 receptor subtypes [24] . The resulting peptide N-a -fluoresceinyl- [29] . The lateral mobility of the adenylyl cyclase-coupled V2 AVP receptor from LLC-PK1 cells was studied using fluorescence photobleaching with these two fluorescent peptides (depicted in Fig. (3) The synthesis and characterization of first generations of fluorescent agonists and antagonists for AVP/OT receptors led to the discovery of very promising pharmacological tools but their use was limited to fluorescence microscopy techniques applied to the investigation of the cellular expression and localization of receptors. Indeed, the sensitivity of the fluorophores attached to these ligands was far from being equivalent to that of usual radioisotopes ( 3 H, 125 I), and ligand binding assays could not generally be developed.
Novel generations of fluorescent analogs for AVP and OT receptors.
Since 1992, the different AVP/OT receptor genes or cDNAs were all cloned from different mammals, lower vertebrate and invertebrate species [8] [9] [10] [11] . receptors in rat hepatocytes [43, 44] . A high affinity is also crucial for cellular and subcellular analysis and colocalization with other markers in fluorescence microscopy. Fluorescence recovery after photobleaching could also be used to study the diffusion of fluorescent probes in a tissue or in one cell. Fluorescence correlation spectroscopy which allows the detection of interactions between one receptor molecule and one ligand molecule is also a very interesting application. Structural information for ligand-receptor interactions could also be obtained by fluorescence quenching, polarization, or FRET (fluorescence resonance energy-transfer) experiments using these compounds.
Cyclic peptide agonists and antagonists with classical fluoresceinyl and
tetramethylrhodamyl fluorochromes.
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We next reported the design and synthesis of new fluorescent OT antagonists and agonists and their pharmacological properties for the AVP/OT receptors. Again, fluoresceinyl and tetramethylrhodamyl groups were coupled to parent peptides through an amide bond to the side chain amino group at position 8 [45] . Fig. (3) ), the first one only having a good affinity for the OTR (K i was around 6 nM). More interestingly, it was selective for this receptor. These properties rendered the ligand very useful for specifically labelling cell surface OTR in tissues, freshly dissociated cells or in primary cell cultures. All other ligands of the series were fluorescent agonists deriving from OT agonists lacking the a-NH 2 group at position 1 and for which the leucine residue at position 8 was replaced with an ornithine or a lysine for attachment of the fluorophore [45] . (the three peptides are shown in Fig. (2) ). Fluorescence microscopy labelling of CHO and HEK cells stably or transiently expressing the human OTR, respectively, was realized in order to study the distribution of the receptor and its internalization process. OTR-expressing myocytes of human myometrum during parturition. These fluorescent ligands could also be used to perform fluorescence recovery after photobleaching to study the diffusion of molecules in a tissue or in a single cell or to obtain structural information for ligand-receptor interactions by fluorescence quenching, polarization or FRET.
linear peptide antagonists with novel Alexa and Europium cryptate fluorochromes.
As indicated in the introduction, GPCRs represent the single largest molecular target of therapeutic drugs currently on the market, but are also the most common target in highthroughput screening (HTS) assays for identifying potential new drug candidates. Most of these HTS procedures are still presently based on radioligand binding competition assays. 
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However, no evidence of direct receptor-receptor interactions has yet been provided in native tissues. We have recently used a FRET approach to address this question with pairs of labeled ligands, one with the Alexa 647 the other with the EuÃ PBBP [52] . Indeed, OTR dimers/oligomers in the mammary glands of lactating rats were unambiguously identified using (28) . These two agonists are seen in Fig. (2) . Interestingly, due to a high affinity for the V1a receptor, these pairs of ligands should be useful to the demonstration of Unfortunately, the search for a peptide agonist/antagonist selective for the human V2 receptor with respect to the V1a, V1b and OTR is still a challenging goal [16] . V2 antagonists with high affinity but which are nonselective have been developed [53] . 
